A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest Huntington’s disease (HD)

Sep 16, 2018

Extract of the plenary session by Roche lead scientist Scott Schobel at EHDN 2018 outlining the design of the Global Development Program for RG6042 in HD. The slides made available are an extract of the plenary presentation and are a fair and balanced representation of the content presented.

Current View

Receive this presentation and more content via email